Catalog #
LDN-02; LDN-10; LDN-50
StemRD LDN-193189 小分子工具 产品英文简述：
A selective inhibitor of bone morphogenetic protein （BMP） type I receptors （ALK-2 and ALK-3）. Only weakly inhibits ALK-4,-5, and -7.
4-[6-（4-Piperazin-1-yl-phenyl）-pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline
Ref: Cuny, G.D., et al. Structure-activity relationship study of bone morphogenetic protein （BMP） signaling inhibitors. Bioorg Med Chem Lett 18: 4388-92, 2008.
Catalog #
LDN-02; LDN-10; LDN-50
Description
A selective inhibitor of
bone morphogenetic protein (BMP) type I receptors
(ALK-2 and ALK-3). Only weakly inhibits ALK-4, -5,
and -7.
4-[6-(4-Piperazin-1-yl-phenyl)-pyrazolo[1,5-a]pyrim
idin-3-yl]-quinoline
Ref: Cuny, G.D., et al. Structure-activity relatio
nship study of bone morphogenetic
protein (BMP) signaling inhibitors. Bioorg Med Chem
Lett 18: 4388-92, 2008.
Formulation
Powder
Reconstitution
Before reconstitution, we recommend a brief spin to drive down a
ny
material dislodged from the bottom of the tube. The compound is soluble
in DMSO.
Stability
The powder is stable for at least 2 year if stored at -20
degree C. The
dissolved compound is stable for at least 1 month at 4 degree C, but
should
be stored in aliquots at -20 degree C for longer term. Protect from light.
Purity
Greater than 98% as determined by LC/MS analysis. LC/MS a
nd/or NMR
data available upon request.
Biological Activity
Not determined.
Structural Info
MW:
406.48
Formula:
C25H22N6
Solubility:
Soluble in DMSO at 10 mM.
CAS:
1062368-24-4
For Research Use Only. Not for Use in Humans.
• Purity: Greater than 98% as determined by LC/MS analysis.
• Biological Activity: Not Determined
